Kezar Life Sciences (KZR) Competitors $4.56 +0.07 (+1.56%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. SKYE, IMRX, INMB, NMRA, FTLF, GLSI, FATE, PLX, NKTX, and CRBUShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Skye Bioscience (SKYE), Immuneering (IMRX), INmune Bio (INMB), Neumora Therapeutics (NMRA), FitLife Brands (FTLF), Greenwich LifeSciences (GLSI), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Nkarta (NKTX), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors Skye Bioscience Immuneering INmune Bio Neumora Therapeutics FitLife Brands Greenwich LifeSciences Fate Therapeutics Protalix BioTherapeutics Nkarta Caribou Biosciences Skye Bioscience (NASDAQ:SKYE) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Does the media favor SKYE or KZR? In the previous week, Kezar Life Sciences had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Kezar Life Sciences and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.02 beat Kezar Life Sciences' score of -0.67 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kezar Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has more volatility & risk, SKYE or KZR? Skye Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Is SKYE or KZR more profitable? Skye Bioscience's return on equity of -53.92% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -53.92% -48.58% Kezar Life Sciences N/A -61.15%-50.27% Which has preferable valuation and earnings, SKYE or KZR? Skye Bioscience has higher earnings, but lower revenue than Kezar Life Sciences. Skye Bioscience is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$0.82-5.58Kezar Life Sciences$7M4.76-$83.74M-$10.82-0.42 Do institutionals & insiders have more ownership in SKYE or KZR? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 4.5% of Skye Bioscience shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer SKYE or KZR? Skye Bioscience currently has a consensus target price of $16.60, indicating a potential upside of 262.84%. Kezar Life Sciences has a consensus target price of $39.50, indicating a potential upside of 766.23%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummarySkye Bioscience beats Kezar Life Sciences on 8 of the 14 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.33M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-0.4221.5627.6020.30Price / Sales4.76172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book0.287.518.055.68Net Income-$83.74M-$55.05M$3.18B$249.13M7 Day Performance2.70%4.61%2.82%3.30%1 Month Performance7.04%4.89%3.70%5.20%1 Year Performance-21.26%5.84%35.41%21.38% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences4.1799 of 5 stars$4.56+1.6%$39.50+766.2%-21.3%$33.33M$7M-0.4260SKYESkye Bioscience2.552 of 5 stars$4.18+1.7%$16.60+297.1%-38.7%$127.31MN/A-5.1011Positive NewsHigh Trading VolumeIMRXImmuneering4.1069 of 5 stars$3.37-4.5%$13.25+293.2%+200.0%$127.03M$320K-1.7260Positive NewsGap UpINMBINmune Bio1.6336 of 5 stars$2.31-56.7%$22.80+887.0%-67.4%$122.50M$10K-1.2010News CoverageAnalyst ForecastGap DownHigh Trading VolumeNMRANeumora Therapeutics2.6138 of 5 stars$0.73-3.1%$9.29+1,166.3%-91.7%$122.43MN/A-0.46108Gap UpFTLFFitLife Brands4.0657 of 5 stars$13.02+1.6%$20.50+57.5%-7.3%$120.30M$64.47M15.5020GLSIGreenwich LifeSciences1.5357 of 5 stars$9.07+0.9%$39.00+330.0%-39.9%$120.18MN/A-7.203FATEFate Therapeutics4.1817 of 5 stars$1.12+7.7%$3.83+242.3%-63.8%$119.19M$13.63M-0.75550News CoverageAnalyst RevisionGap DownPLXProtalix BioTherapeutics2.9406 of 5 stars$1.48-3.9%$15.00+913.5%+45.8%$117.82M$59.76M-11.38200Gap UpNKTXNkarta2.2838 of 5 stars$1.66flat$14.33+763.5%-67.2%$117.79MN/A-1.10140CRBUCaribou Biosciences2.3387 of 5 stars$1.26flat$8.50+574.6%-15.0%$117.19M$9.99M-0.78100News Coverage Related Companies and Tools Related Companies SKYE Competitors IMRX Competitors INMB Competitors NMRA Competitors FTLF Competitors GLSI Competitors FATE Competitors PLX Competitors NKTX Competitors CRBU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
